Hormonal treatment in pregnancy: A possible risk factor for neuroblastoma

M. Mandel, A. Toren, G. Rechavi, J. Dor, I. Ben‐Bassat, Y. Neumann

Research output: Contribution to journalArticlepeer-review


In the last 4 years, 24 cases of neuroblastoma were treated in the Pediatric Hematology‐Oncology Unit at the Chaim Sheba Medical Center, 8 of whom were under 1 year of age. Four of them were the product of a pregnancy‐induced or preserved by gonadotropins, clomiphene citrate, or progestational hormones. These drugs are known to produce a higher than normal level of estradiol or progestrone in the early stages of pregnancy. Our observation led to the hypothesis that high levels of progestational hormones given during pregnancy are a risk factor for neuroblastoma in infancy. © 1994 Wiley‐Liss, Inc.

Original languageEnglish
Pages (from-to)133-135
Number of pages3
JournalMedical and Pediatric Oncology
Issue number2
StatePublished - 1994


  • gonadotropins
  • neuroblastoma in infancy
  • neuroblastoma in situ
  • progestational hormones


Dive into the research topics of 'Hormonal treatment in pregnancy: A possible risk factor for neuroblastoma'. Together they form a unique fingerprint.

Cite this